Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2026 Mar 10;16:8514. doi: 10.1038/s41598-026-42796-2

Correction: Bevacizumab enhances overall survival in newly diagnosed glioblastoma patients with high COX-2 expression

Irfan Kesumayadi 1, Atsushi Kambe 1,, Haruto Kanda 1, Tomohiro Hosoya 1, Makoto Sakamoto 1, Masamichi Kurosaki 1
PMCID: PMC12976151  PMID: 41807522

Correction to: Scientific Reports 10.1038/s41598-026-35550-1, published online 10 January 2026

The original version of this Article contained an error in Figure 1, where panels c and d were incorrectly labelled Hematoxylin in contrast to the correct legend label of COX-2.

The original Figure 1 and accompanying legend appears below.

Fig. 1.

Fig. 1

(a) IRS of COX-2 expression: The median IRS value across all groups was 3, with IRS ≥ 3 classified as high COX-2 expression. (b) ∆Ct analysis of COX-2 expression revealed significantly lower mean ∆Ct values in the high-expression group, indicating higher mRNA levels compared to the low-expression group. Representative immunohistochemistry (IHC) staining images show (c) low COX-2 expression with an IRS of 1, derived from an intensity score of 1 and a positivity cell rate of 1, and (d) high COX-2 expression with an IRS of 9, derived from an intensity score of 3 and a positivity cell rate of 3.

The original Article has been corrected.


Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES